Ebrasodebart
Autoimmune Disorders (specifics not fully detailed)
Preclinical or Early ClinicalActive
Key Facts
Indication
Autoimmune Disorders (specifics not fully detailed)
Phase
Preclinical or Early Clinical
Status
Active
Company
About Enthera Pharmaceuticals
Enthera Pharmaceuticals is a private, clinical-stage biotech pioneering a novel therapeutic approach for autoimmune diseases by targeting the IGFBP3/TMEM219 apoptosis pathway. Its lead candidate, Ent001, is in Phase 1 development with the potential to modify disease progression in Type 1 Diabetes and Inflammatory Bowel Disease by protecting and restoring stem cells. Backed by notable life science investors like Sofinnova Partners and JDRF, the company is advancing a pipeline of monoclonal antibodies and fusion proteins derived from its proprietary discovery engine to address significant unmet medical needs.
View full company profile